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Abstract
In Alzheimer’s disease (AD), early deficits in learning and memory are a consequence of synaptic modification induced by
toxic beta-amyloid oligomers (oAb). To identify immediate molecular targets downstream of oAb binding, we prepared
synaptoneurosomes from prefrontal cortex of control and incipient AD (IAD) patients, and isolated mRNAs for comparison
of gene expression. This novel approach concentrates synaptic mRNA, thereby increasing the ratio of synaptic to somal
mRNA and allowing discrimination of expression changes in synaptically localized genes. In IAD patients, global measures of
cognition declined with increasing levels of dimeric Ab (dAb). These patients also showed increased expression of
neuroplasticity related genes, many encoding 39UTR consensus sequences that regulate translation in the synapse. An
increase in mRNA encoding the GluR2 subunit of the a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor
(AMPAR) was paralleled by elevated expression of the corresponding protein in IAD. These results imply a functional impact
on synaptic transmission as GluR2, if inserted, maintains the receptors in a low conductance state. Some overexpressed
genes may induce early deficits in cognition and others compensatory mechanisms, providing targets for intervention to
moderate the response to dAb.
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Introduction
Synaptic dysfunction and loss in Alzheimer’s disease (AD) are
correlates of cognitive impairment [1,2] emphasizing the impor-
tance of identifying early molecular changes at the synapse. Early
in the course of AD, synaptic dysfunction, which is present before
the accumulation of histopathological hallmarks of AD, may be
reversible [3,4].
Initially, amyloid plaque pathology in AD was thought to
correlate positively with clinical progression of the disease [5] until
the toxic effects of soluble beta-amyloid (Ab) peptides, both Ab1-
40 and Ab 1-42, were strongly associated with cognitive decline
even in the absence of significant tau pathology [6]. oAb is
implicated specifically in targeting the synapse by binding to cell
surface receptors [7–9], an interaction which provides a molecular
basis for reversible memory loss in the Tg2576 transgenic mouse
model of AD [10,11]. Accumulation of dAb in transgenic mice
occurs concurrently with memory impairment, suggesting a causal
role [12] although, trimers have also been suggested as the most
active toxic species in mouse hippocampal, long term potentiation
(LTP) inhibition [13]. In rats, intracerebroventricular injection of
oAß induces transient disruption of working memory [14,15] and
organotypic slices incubated with oAb show loss of dendritic spines
and a decrease in excitatory synapses mediated by activity of N-
methyl-d-aspartate receptor (NMDARs) through a pathway
involving cofilin and calcineurin [16] These conditions favor
reduction in LTP and facilitation of long term depression (LTD)
and, although LTP and LTD are experimental in vitro phenomena,
a comparable modification in synaptic plasticity may occur in vivo,
early in AD. Aß also impacts AMPAR mediated currents [17].
Studies showing inhibition of AMPAR transmission after bath
application of Aß [18] and synaptic silencing through a selective
reduction in AMPARs in primary cultured neurons overexpressing
amyloid precursor protein (APP) [19] infer a crucial role in AD
pathogenesis. However, mouse models do not reflect the full
pathogenesis of AD and although human genetic, epigenetic and
behavioral variability add complexity to such analyses, the ability
to use the human central nervous system (CNS) provides a very
PLoS ONE | www.plosone.org 1 March 2009 | Volume 4 | Issue 3 | e4936powerful and corroborative approach for understanding disease
progression [20]. Recent reports have pushed the boundaries of
experiments using postmortem human CNS tissue in complex
diseases, such as schizophrenia, [21] .
Microarray analyses of the human CNS have been used
extensively to define changes in gene expression in pathways of
learning and memory [22], aging [23], and neurodegenerative
diseases [24]. Previous microarray studies compare whole
homogenates or even single cells obtained postmortem from
control and AD brains [25–29] and provide data that is relevant to
the disease. Blalock [30] analyzed hippocampal tissue obtained
from patients with minimal cognitive impairment (MCI) as well as
more severe dementia to target early changes in gene expression.
We also focus on early changes in mRNA expression that may
occur prior to formation of amyloid plaques and neurofibrillary
tangles (NFTs). Our study examines a spectrum of patients ranging
from controls to those with incipient AD (IAD), which combines
patients with MCI and early AD categorized by neuropsycholog-
ical changes in global executive and memory functions. As the
hippocampus sustains neuropathological changes early in the
disease and few patients come to autopsy with only entorhinal
cortical change, we analyze postmortem prefrontal cortex
(Brodmann’s areas 9 and 10) with absent or minimal Ab or tau
fibrilization. In AD, prefrontal cortex is the site of early neocortical
changes [31], and also provides sufficient quantities of tissue for
microarray and biochemical analysis. Also, other limbic system
sites, such as anterior cingulate gyrus, cannot be readily
neuropsychologically evaluated.
Plasticity, memory encoding and consolidation are dependant
on local protein synthesis, initiated and regulated on site within the
synapse [32,33]. Thus perturbation by Ab of receptor binding and
signaling at the synapses may disrupt local translation and thereby
initiate the cascade of molecular events which negatively impact
cognition and initiate neurodegeneration. The relevance to AD of
39UTR regulatory sequences and local protein synthesis at the
synapse are largely unexplored. In primary rat neuronal cultures,
axons, dendrites and their synaptic terminals contain only about
3.9% of the cellular total RNA [34]. Thus, functionally significant
changes in synaptic mRNAs during the course of AD may be
masked by more abundant species in microarray analyses using
total cellular mRNA isolated from neuronal somata, glia and other
cells. To elucidate the effects of oAb on synaptic mRNA, we used
synaptoneurosomes prepared from the prefrontal cortex to enrich
synaptic mRNAs for microarray analyses.
The sensitivity of our approach reveals early expression change
in neuroplasticity genes, including those regulated and translated
at the synapse. The GluR2 subunit of AMPAR shows elevated
gene and protein expression in IAD concomitant with elevating
levels of dAb. Our results may suggest a spectrum of therapeutic
targets during dementia progression in AD.
Results
Cognitive function and neuropathology
Global cognition and function were evaluated by the Mini-
Mental Status Examination (MMSE) and Clinical Dementia
Rating Scale (CDR) testing (see Supplemental Methods S1 and
data Table S1). Our subjects were categorized primarily on
MMSE data into two groups: controls (MMSE 30-25) and
‘‘Incipient AD’’ (MMSE 21-26, with MCI 24-26 and mild AD
21-23). Some subjects in the control group had amyloid plaques
and/or NFTs. We reasoned that patients with pathology yet good
cognitive function may yield insights into protective or compen-
satory mechanisms. After careful review of neuropsychological and
neuropathological data, two borderline cases both with MMSE 25
(1 Control and 1 IAD) were assigned based not only on MMSE,
but also NFT, amyloid plaque and Braak stage data (not shown). A
clear distinction is not always possible within the transitional
border between control and MCI. We considered MMSE and
CDR as well as the neuropathology, especially, NFTs. For
example in Table S1, the last control shows an MMSE of 25
and CDR 0.5, but the prefrontal cortex has no pathology. The
hippocampal section showed minimal NFTs (not shown) and an
overall Braak score of III. Mild depression was noted by
neuropsychologists at the last patient interview which may have
lowered her test scores. The first patient in the IAD set has an
MMSE of 25, CDR1 and again no prefrontal cortical neuropath-
ologic changes. However, the hippocampus has severe NFT’s (not
shown) yet a Braak score of III and was placed in the IAD group.
Overall, the variability of MMSE, and the indistinct Braak values
complicate diagnoses at transitional points.
There were no significant group differences in executive
function measures; the composite or Digit Span backward
(p.0.05), (Table S1). There was a trend for a decline in recall
with controls recalling more words after a delay than IAD patients
(p,0.08). These results are more indicative of neuropathological
changes in the hippocampus as reflected in most Braak scores.
Controls showed no significant change in working memory, the
ability to temporarily store and manipulate information (p,0.13).
Statistical interpretation must be made with caution given the
small sample size. No significant group differences were found
with measures of memory retention.
Enrichment and functional stability of synaptic mRNAs
To augment studies comparing homogenates of control to AD
brains, we used synaptoneurosome preparations [35] to enrich
synaptic mRNAs. Synaptoneurosomes were prepared from the
prefrontal cortices of control and IAD patients by a simple, rapid,
but gentle method using sequential mesh screens. Preparations
were analyzed for residual nuclei by applying 49-6-Diamidino-2-
phenylindole (DAPI)-containing mounting media to smears of
each pellet. The percentage of nuclei in the synaptoneurosome
pellet was reduced to 0.4% of those in the homogenate (Figure 1A,
1B) and are, therefore, a minor source for contaminating mRNAs.
Most nuclei were observed densely packed in the first pellet (P1,
not shown).
Morphologic integrity of synaptoneurosomes was confirmed by
phase contrast microscopy. We observed pre-and postsynaptic
‘‘snowman’’ profiles (0.3–0.7 mm) in the size range, expected for
synaptoneurosomes (Figure 1C). Ultrastructurally, these profiles
consist of intact pre- and postsynaptic terminals with typical
synaptic vesicles in the presynaptic terminal and a well-preserved
postsynaptic density (Figure 1D, E) comparable to those isolated
from rat brain [35]. These observations suggest that sufficient
synaptoneurosomes remain morphologically intact for extraction
of synaptic mRNAs. Myelin profiles and empty membranous
structures were also noted.
To verify preservation and enrichment of synaptic proteins, we
probed immunoblots of homogenates and synaptoneurosome
pellets from normal controls with antibodies to synaptic proteins
and other potential contaminating species. Immunoreactive
proteins were quantified by densitometry and normalized to
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) detected in
each sample lane. There is an increase in post-synaptic density
protein 95 (PSD-95) (62.3), NMDAR1 (68.0), GluR2 (62.1) and
synaptosomal-associated protein, 25 kDa (SNAP25) (61.7) in
synaptoneurosomes compared to homogenates. Using PSD-95
for comparison, our enrichment of synaptic proteins is similar to
Genes Overexpressed in IAD
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prepared in our laboratory (results not shown) . Protein kinase Ca
(PKCa), a cytoplasmic proteins which is active in synapses, is
slightly more abundant in synaptoneurosomes (61.4) but b-tubulin
(60.8) is not. A decrease (60.4) in glial fibrillary protein (GFAP),
indicates reduction of astrocytes comparable to that found by
others [38] (Figure 1F).
The functionality of mRNAs was assessed by an in vitro
translation assay. To detect translation products, we used
Transcend
TM tRNA which is an e-labeled biotinylated lysine-
tRNA complex with a detection sensitivity of 0.5–5 ng of protein.
Initially, we used pooled mRNA isolated from the frontal cortices
of either control or IAD patients and incubated with rabbit
reticulocyte lysate (RRLs) and Transcend
TM tRNA. Newly
synthesized, biotinylated proteins were detected on immunoblots
(Figure S1A). Next, to determine if the postsynaptic translation
apparatus is functional, we incubated the synaptoneurosomes with
Transcend biotinylated tRNA, but without RRLs. We observed
several bands representing newly translated biotinylated protein
detected with streptavidin (Figure 1G,). One lane, containing only
the basal reaction, was probed with antibody to the a-subunit of
Ca
++ calmodulin-dependant protein kinase II (aCAMKII) and
revealed a band with identical migration to a newly synthesized
protein at 50 kD. Although this is not definitive proof of the
identity of the 50 kD band, synthesis of aCAMKII has been
demonstrated previously in synaptoneurosomes isolated from rat
brain [39]. Incubation with actinomycin, a transcription inhibitor,
did not change the band profiles. However in samples incubated
with the translation inhibitor anisomycin newly synthesized bands
were not detected. Endogenously biotinylated bands at ,140 and
,75 kD were found in all lanes of all immunoblots of
synaptoneurosomes detected with streptavidin, and serve as
loading controls [40]. To confirm the reproducibility of the
translation assay we tested synaptoneurosomes from three controls
and two IAD patients. Basal translation profiles (Figure S1B) show
bands, other than endogenously biotinylated bands, at a range of
molecular weights similar to results from mouse synaptoneuro-
somes [36,39]. An increase in the amount of protein loaded and
variations in Western blotting and detection are likely factors
influencing the number of bands detected. Our results indicate
that synaptoneurosomes isolated from human postmortem brain
tissue contain functional mRNA and the protein translation
components necessary for de novo synthesis of proteins from locally
positioned mRNA.
Oligomeric Ab Expression
To correlate dementia profiles with oAb expression, Western
blots of homogenates from the frontal cortices of control, IAD and
moderate to severe AD patients were probed with antibody 4G8,
which detects oAb1-42. A ,9 kD band consistent with the dAb
was found and increased in intensity with degree of cognitive
impairment, as defined by declining MMSE scores (Figure 2A, C).
Additional bands of higher molecular weight were identified by
MAb 4G8 in homogenates, but their variability of expression was
not consistent with disease progression (Figure S2A). For instance,
densitometric comparison of dAb in control compared to IAD and
Figure 1. Enrichment and stability of synaptoneurosomes.
Microscopy: A) Nuclear contamination of the homogenate (2 ml
smears) (DAPI fluorescence) decreases after sequential passage through
mesh screens with B) the post- 10 mm screen synaptoneurosome pellet
(100 ml volume) still retaining a few nuclei (Bar=20 mm). C) Intact
synaptoneurosomes are detected by phase contrast in smears of
pelleted post-10 mm screen synaptoneurosome as typical ‘‘snowman’’
pre- and postsynaptic profiles (arrowheads). Larger, empty, membra-
nous structures are also observed. (Bar=5 mm). D) Electron microscopy
reveal ‘‘snowman’’ profiles with apparent postsynaptic densities
(arrowheads); (Bar=300 nm). E) At higher magnification, presynaptic
terminals containing synaptic vesicles, 20 nm in size (white arrows) are
indicated (Bar=100 nm). Immunoblots: F) Homogenates (black bars)
and synaptoneurosomes (white bars) were compared for stability and
enrichment of synaptic proteins and contamination with other cellular
debris. Densitometric comparison on immunoblots of postsynaptic
proteins PSD-95, NMDAR1 and GluR2 in synaptoneurosomes shows
more than a two-fold enrichment compared to homogenates, an
increase in presynaptic protein SNAP-25 but a 40% decrease in glial
protein GFAP. Cytoplasmic proteins b-tubulin and PKCa show little
change. The ratio of each protein to GAPDH is given in arbitrary units
based on the integrated density value which is the sum of all pixel
values after background correction (IDV). G) In synaptoneurosomes, de
novo synthesis of several proteins is observed as newly translated,
biotinylated proteins detected with streptavidin (lane 1), and one at
50 kD co-migrates with a band detected with antibody to aCAMKII
(lane 4,arrowhead). Actinomycin D, a transcription inhibitor, does not
reduce the protein band profile (lane 2). Protein synthesis is inhibited by
the translation inhibitor, anisomycin (lane 3), although endogenously
biotinylated proteins present in synaptoneurosomes are still seen at
,140 and 75 kD (asterisks).
doi:10.1371/journal.pone.0004936.g001
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increase as the disease progressed whereas an apparent tetramer
(tAb) did not increase in IAD and declined in AD (Figure S2B).
Because of the small number of samples in each group, and
variability within control and IAD groups, the change in dAb is
not significant. To discriminate the dAb from the C-terminal stub,
CT-83, which migrates close to 8 kD we used MAb 6E10 which
confirmed the ,9 kD species as dAb (Figure S2C). Another
predictor of dAb expression is the ApoE4 genotype, as dimers were
detected in all patients with at least one ApoE4 allele, including one
control. A later evaluation of dAb in IAD and AD with more
patients in the IAD and AD groups, but without the confounding
effect of one control with ApoE4 genotype and increased dAb,
showed the elevation of dAb levels to be significant (data not
shown). dAb abundance in synaptoneurosome preparations also
increased as the MMSE declined (Figure 2B). Comparison of the
Aß dimer normalized to GAPDH in homogenates and synapto-
neurosomes showed a consistent quantitative increase with the
duration of disease (Figure 2C).
Microarray analysis
The yield of RNA (10 mg) from synaptoneurosomes prepared
from 1gram of tissue was sufficient for probe generation. Only
samples with well defined ribosomal peaks at 28S and 18S were
included in the study. All 15 patients initially chosen for our study
yielded mRNA suitable for microarray analysis with one
preparation discarded later due to poor hybridization. Bioinfor-
matics analysis revealed moderate degradation of cRNA tran-
scripts towards the 59 end in most samples. However, varying
degrees of degradation create a reduction in transcript length, not
a reduction in the amount of transcripts, and agonal state,
postmortem interval (PMI) and pH have not been found to
correlate significantly with RNA degradation [41]. Stringent
protocols cannot be fully imposed on postmortem human tissue
and only PMI can be somewhat controlled by efficient
coordination of autopsy procedures. Initial RNA transcript quality
has some effect on the microarray absolute call and signal strength
but later quality control screens identify samples with significant
degradation as outliers.
The Affymetrix Human Genome HG-U133A chip contains
22,215 transcripts. A 2-way ANOVA test was applied to identify
genes with changed expression at three levels of significance p,0.05,
p,0.01 and p,0.001or p,0.01 with 1.4+fold change (fc)
(Figure 3A). The ratio of genes with increased compared to
decreased expression in IAD was 1.3 fold at p,0.05, 1.8 fold at
p,0.01 and 8 fold at p,0.001or p,0.01fc 1.4 (Figure 3B). Gene
name, gene symbol, functional classification and p-value of all genes
are given in supplementary data, (Table S2). We used the p,0.01
analysis for hierarchical clustering which reveals a spectrum of gene
expression changes in the heatmap (Figure 3C) with 5 patients (3
controls and 2 IAD) under the blue bar, seemingly on the cusp of the
more dramatic changes seen in IAD patients on the far right. The
data discussed in this publication are MIAME (Minimum
Information About a Microarray Experiment) compliant and have
been deposited in the Gene Expression Omnibus (GEO) at the
National Center for Biotechnology Information [42], and is
accessible through GEO Series accession number GSE12685
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=12685).
Functional analysis of genes overexpressed in IAD
The analytical tools at DAVID Bioinformatic Resources
(http://david.abcc.ncifcrf.gov) were used to generate a list of gene
ontology categories containing genes with changed expression in
IAD. All genes in the p,0.01 list were included in the analysis
regardless of fold change. We focused on the category Biological
Processes and identified 11 significantly overrepresented themes
(EASE score ,0.06) constituting four categories (Table 1),
including synaptic transmission (p,0.013), neuronal cell-recogni-
tion (p,0.005) and vesicle transport (p,0.007), all essential for
synaptic function and plasticity. One other category, glucose
catabolism, may be related to more general metabolic changes in
IAD [43]. Chromatin remodeling (p,0.06) and regulation of cell-
cycle (p,0.015) categories contain downregulated transcripts.
Neuroplasticity and synaptic terminal function
To augment the results of EASE analysis we analyzed the genes
in Table S2 (p,0.01) with the web-based IngenuityH Pathway
Analysis software (IngenuityH Systems, http://www.ingenuity.
com). The functional analysis identifies the biological functions
and/or diseases that were most significant to the data set (Figure
S3). As the two most significant categories contain many of the
same genes, we chose to focus on genes with expression changes of
1.4 or greater within the larger category ‘‘Nervous system function
and development’’ (2log4 significance) (Table 2, and for the
complete list Table S3), which includes GluR2 (designated GRIA2)
and the glutamate transporter 2 (SCL1A2), both relevant to
neuroplasticity. The muscarinic acetylcholine and serotonergic
neurotransmitter receptors are also of interest. Increased expres-
sion of GABRA1, GABRA2 and GABBR2 suggests activation of
Figure 2. Oligomeric Ab increases with dementia progression.
Oligomeric Ab dimer (dAb) is detected with antibody 4G8 on
immunoblots of A) whole homogenate or B) synaptoneurosomes
prepared from patients with a range of MMSE scores (29-15). A band
observed at ,10 kD with a migration identical to dAb, is detectable in
IAD patients with MMSE scores of about 26 or less. In C) densitometry
reveals that, when normalized to GAPDH, dAb levels are inversely
related to MMSE although patients with an ApoE4 allele (including one
control) exhibit higher concentrations of dAb than patients with
comparable MMSE scores but no E4 allele. Homogenate (grey bar) and
synaptoneurosome (white bar) samples show increasing dAb in IAD as
the disease progresses. Data are representative of 3 separate
experiments. The ratio of dAb to GAPDH is given in arbitrary units
based on the integrated density value which is the sum of all pixel
values after background correction (IDV).
doi:10.1371/journal.pone.0004936.g002
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PLoS ONE | www.plosone.org 4 March 2009 | Volume 4 | Issue 3 | e4936Figure 3. Microarray and Cluster Analysis. In A) Genes were filtered out on the ‘‘present’’ call (P-call) generated by MAS 5.0 leaving 12,536
genes. A 2-way ANOVA test performed on log10-transformed data comparing control with IAD detects the significantly expressed genes. Changes in
gene expression in the IAD patients were evaluated at 3 levels of significance (p,0.05, p,0.01, p,0.001) for patients grouped by MMSE values and
summarized in the chart below, B). We used the p,0.01 analysis gene list for further study. In C), cluster analysis shows relative mRNA message in
controls (black bar) and IAD patients (green bar) with increased expression (green to red) or decreased expression (red to green). Blue line above the
heatmap encompasses patients with gene profiles transitional between control and IAD. See Table S2 for genes lists with gene name, symbol and
fold change.
doi:10.1371/journal.pone.0004936.g003
Table 1. EASE analysis.
Gene Category: Increased Expression EASE score Gene Category: Decreased Expression EASE score
intracellular transport 0.002 chromatin remodeling 0.006
neuronal cell recognition 0.005 non-covalent chromatin modification 0.006
vesicle-mediated transport 0.007 response to chemical substance 0.012
transport 0.010 regulation of cell cycle 0.015
synaptic transmission 0.013 chromatin modification 0.040
transmission of nerve impulse 0.017 alcohol metabolism 0.051
glucose catabolism 0.029 carboxylic acid metabolism 0.053
cell recognition 0.037 cell cycle 0.063
intracellular protein transport 0.037
Golgi vesicle transport 0.040
hexose catabolism 0.042
Using EASE (http://david.abcc.ncifcrf.gov/), genes with increased expression in IAD are significantly overrepresented in gene ontology biological process categories that
are important for synaptic function such as synaptic transmission, neuronal cell recognition and vesicle-mediated transmission. Genes with decreased expression in IAD
are significantly overrepresented in categories relevant to chromatin modification, cell-cycle and carbohydrate metabolism. EASE score equals the upper bound of the
distribution of Jacknife Fisher exact probabilities given the List Hits, List Total, Population Hits and Population Total. Upregulated genes (303) and downregulated genes
(157) were separately analyzed with EASE.
doi:10.1371/journal.pone.0004936.t001
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the focus genes (p,0.01 group) which were algorithmically
generated from information contained in the Ingenuity Pathways
Knowledge Base based on their connectivity (Table S4). Network
#3 (Figure S4A) contains 37 genes involved in neurological
disease, 22 of which are overexpressed in IAD and Network #4
(Figure S4B) contains 26 genes contributing to nervous system
function and development, 17 of which are overexpressed in IAD
(Figure S4). Including genes which interact with GluR2 in
Network 4 demonstrates the potential repercussions of changes
in expression levels of one gene (Figure S4C).
Local translation at the synapse
Increased expression of mRNA species translated at the synapse
may impact synaptic function in IAD. The 39 UTR of each gene
with changed expression in IAD was analyzed for four potential
consensus sequence sites regulating translation; the cytoplasmic
polyadenylation element (CPE) [44–46], the fragile X mental
retardation 1 (FMRP) binding G-quartet [47], the AU-rich
element which binds to the mRNA binding protein, HuD [48],
and a putative pumilio binding site [49]. As seen in Table S5, 24 of
49 encode at least one of these putative regulatory sequence(s) in
the 39UTR, and 10 of these contain more than one regulatory
sequence. Twenty-five mRNAs do not contain any of the
consensus sequences although two of these genes, GAP-43 and
neurogranin (NRGN), important for neuroplasticity, are known to
encode other regulatory elements.
Expression of GluR2 mRNA and corresponding protein
To quantify the differential expression patterns determined by
microarray, synaptoneurosome mRNA from 5 control and 5 IAD
patients was tested by quantitative RT-PCR. Genes selected from
the microarray data set represented a spectrum of function.
Quantitative RT-PCR analyses confirmed the mRNA expression
changes detected in the microarray between control and IAD
patients (Figure 4) and indicate a higher fold change in IAD with,
GLUT1 (63.0, p,0.01) and GluR2 (63.5, p,0.03).
GluR2 was selected to determine if protein expression correlates
with the increased mRNA seen in synaptoneurosomes from
Table 2. Nervous system function and development genes upregulated with $1.4 fold change in IAD.
GENE SYMBOL GENE NAME Fold change
CHRM3 cholinergic receptor, muscarinic 3 2.3
GRIA2 glutamate receptor, ionotropic, AMPA 2 (GluR2) 2.3
NRGN neurogranin (protein kinase C substrate, RC3) 1.9
SLC1A2 solute carrier family 1 , member2 (GLT2) 1.9
HOMER1 Homer homolog 1 (Drosophila) 1.7
EPHA4 EPH receptor A4 1.8
HTR2A 5-hydroxytryptamine (serotonin) receptor 2A 1.8
THY1 Thy-1 cell surface antigen 1.8
NRXN1 neurexin 1 1.7
GPR51 G protein-coupled receptor 51 1.7
CAMK2B Calcium/calmodulin-dependant protein kinase II beta 1.7
RAB14 RAB14 member RAS oncogene family 1.6
APOE apolipoprotein E 1.5
SV2A synaptic vesicle glycoprotein 2A 1.5
GAP43 growth associated protein 43 1.5
SCN1B sodium channel, voltage-gated, type I, beta 1.5
ARNT2 aryl-hydrocarbon receptor nuclear translocator 2 1.5
PRKCZ protein kinase C, zeta 1.5
LPPR4 Plasticity related gene 1.5
PUM1 Pumilio homolog 1 (Drosophila) 1.4
The IngenuityH category ‘Nervous System Development and Function’ contains many genes involved in synaptic function, including those that are identified by EASE
analysis. Many of these genes encode putative mRNA binding sites for proteins which regulate translation (see Table S5 for information on 39UTR regulatory sequences).
doi:10.1371/journal.pone.0004936.t002
Figure 4. Quantitative RT-PCR confirms upregulation of GLUT1
and GluR2. Total RNA (2 mg) was used to generate cDNA by reverse
transcription using oligo-dT primers. Note increased mRNA levels of
glutamate transporter (GLUT1) and GluR2 in IAD patients compared to
controls. Data are mean values 6SEM comparing 4 control and 4 IAD
patients. bCAMKII and GAP43 do not show significant change in mRNA
levels. GAP-3 (p,0.1), GLUT1 (* p,0.01), GluR2 (# p,0.03), bCAMKII
(p,0.06).
doi:10.1371/journal.pone.0004936.g004
Genes Overexpressed in IAD
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homogenate and synaptoneurosome preparations were separated
by polyacrylamide gel electrophoresis (PAGE). Immunoblots labeled
with anti-GluR2 and GAPDH revealed that, in controls, there is a
significant increase in the GluR2 subunit in synaptoneurosomes
compared to whole homogenates (p,0.0002), confirming the data
presented in Figure 1. In synaptoneurosomes from IAD patients,
GluR2 increased as MMSE declined, whereas total GluR2 in
homogenates remained relatively stable (Figure 5A, B, C). In
Figure 5C, the ratio of synaptoneurosome-associated GluR2 to total
GluR2 present in homogenates increases 2-fold in controls to more
than 3-fold in IAD. The increase in synaptic GluR2 subunits is
masked in homogenates. Thus, IAD patients have increased levels of
GluR2 mRNAatthe synapsewhich generate an increaseinreceptor
subunits.
Discussion
Gene Expression in IAD Patients
Using mRNA isolated from synaptoneurosome-enriched prep-
arations, we distinguished early molecular changes in the brains of
IAD patients which, by current consensus, occur at the synapse
[1,50,51]. We identified a panel of mRNAs with increased
expression in IAD patients which are overrepresented in the gene
ontology, biological process categories of synaptic transmission
and transport. oAb burden was concomitant with a decline in
cognitive function even though these patients had minimal
neuropathological changes in the prefrontal cortex. An increase
in GluR2 expression in IAD patients was accompanied by elevated
expression in the corresponding protein.
Our results are in striking contrast to previous microarray
studies, comparing either whole homogenates or single neurons
from control and AD brains [26–29], which indicate increased
expression in genes coding for inflammation, stress and DNA
repair. Blalock et al [30] in an informative study focused on IAD
compared hippocampal homogenates from 9 controls and 7 IAD
subjects but found that expression values of genes overrepresented
in the categories of synaptic transmission and cell-surface signal
transduction were decreased whereas genes with increased
expression were overrepresented in the category regulation of
transcription. These discrepancies are not unexpected as our
studies differ in several ways. For instance, we used prefrontal
cortex which is affected pathologically after the hippocampus [52]
and therefore might yield data on earlier molecular changes. Also,
as the synapse is likely the site of initial Ab toxicity, we chose to
analyze genes directly impacted by synaptic events which are
localized and translated at the synapse. It is possible that, in IAD,
selective targeting and transport of some mRNAs to the synapse is
modified but total mRNA is not appreciably altered. We found
only 5 overlapping genes in the upregulated category of each study
and no common downregulated genes. Nevertheless the results
from these studies are complementary with our study focusing on
molecular changes at the synapse and that of Blalock et al defining
regional gene expression differences in IAD.
Enrichment of synaptic mRNAs
Isolation of mRNAs from synaptoneurosomes provides a
selective enrichment of a cohort of genes encoding synaptic
terminal proteins locally translated in the synapse. Expression
profiles of genes from whole homogenates of human CNS tissue
reflect a bias in the ratio of whole cell to synaptic mRNA. Thus,
even though our preparations may contain some nonsynaptic,
cellular components [53,54], the enrichment of synaptic mRNAs
enables detection of expression changes in genes, such as GluR2,
at their sites of translation in the synapse, that are masked by more
abundant mRNAs in whole brain homogenates. Our results also
substantiate the prospect of using postmortem human CNS tissues
for functional analysis as described for tissue slices by Hahn [21].
The in vitro protein synthesis assay demonstrates the functional
stability of synaptoneurosomes obtained postmortem providing an
assessment of basal levels of in vitro protein synthesis and the
potential to investigate receptor-based regulation of mRNA
translation at the synapse in neurodegenerative diseases such as
AD.
Dementia progression in IAD and compensatory
neuroplasticity in the prefrontal cortex
Our microarray profiles positively correlate with global
indicators of dementia progression and display a high specificity
and significance for patients with MMSE scores consistent with
IAD. Measures of frontal lobe executive function show no
statistically significant differences in the composite measure of
Digit Span Backwards and neuropathological changes are minimal
to absent. Thus, microarray and protein changes are detectable in
the prefrontal cortex prior to overt behavioral and neuropsycho-
Figure 5. GluR2 protein expression. To determine if increased
GluR2 mRNA generates elevated protein expression, we compared
subjects with a range of MMSE values. Representative immunoblots of
A) homogenates and B) synaptoneurosomes, (10 mg protein per lane)
were detected with antibodies for GluR2 and GAPDH. C) In controls, the
increased ratio (2-fold) of synaptoneurosome (white bar) GluR2 to total
GluR2 in homogenates (* p,0.0002) is an indication of synaptic protein
enrichment and this ratio increases by 50% in IAD patients (p,5.8E-08).
In the IAD group there is a significant increase in synaptoneurosome
GluR2 protein expression compared to control (** p,6.0E-05).
Homogenate GluR2 (black bar) remains constant in controls and IAD.
Data are mean values 6SEM for 4 controls and 4 IAD analyzed in 5
separate experiments. The ratio of GluR2 to GAPDH is given in arbitrary
units based on the integrated density value which is the sum of all pixel
values after background correction (IDV).
doi:10.1371/journal.pone.0004936.g005
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construct however, but can be fractionated into multiple
component parts and includes the ability to focus and shift
attention, to inhibit responses, to think abstractly, and to solve
problems [55]. There was a trend for impaired recall in IAD
patients which may correlate with hippocampal pathology, as
indicated by Braak scores up to III. Thus, in contrast to molecular
profiles, use of tests that measure executive functions other than
working memory cannot definitively differentiate the two patient
groups. Alternatively, our small sample size likely lacked sufficient
power to detect group differences in executive functioning.
In contrast to the decline in cognitive function, our microarray
expression profiles of IAD patients reveal a seemingly paradoxical
increase in mRNAs encoding proteins which regulate synaptic
transmission, plasticity and signal transduction. These results are
not without precedent. Firstly, a morphometric analysis of
antibody staining in brain sections of AD patients up to Braak
stage III reveals an increase in the presynaptic proteins SNAP-25,
synaptophysin, syntaxin and a-synuclein [56]. With further disease
progression, when neocortical neuropathologic changes of AD
appear, the increase is reversed (data not shown) in accord with
other reports comparing control and AD brains which show a
general decrease in synaptic proteins in moderate to severe AD
[57]. Two other synaptic proteins, drebrin, which mediates
synaptic plasticity by regulating spine morphogenesis and receptor
density on spines [22], and the vesicular glutamate transporter 1
(VGluT1), a presynaptic transporter protein are also elevated in
IAD patients [58,59].
These findings dovetail with reports of compensatory plasticity
which is mediated, in part, by ApoE [60]. Increased expression of
ApoE mRNA in IAD patients, along with other plasticity-related
genes, such as growth-associated protein 43 (GAP-43), plasticity
related gene (LPPR4), NRGN, synaptogyrin (SYNGR1) and beta-
synuclein (SNCB) suggest a concerted response. Compensatory
plasticity is further supported by brain functional imaging which
reveal distinct cortical activation patterns suggesting the brain
might substitute alternative pathways to maintain successful task
performance in IAD when confronted with impaired access to
specific task-subserving areas, [61,62]. Functional activation
studies comparing AD and healthy, aging brains [63,64] also
reveal very specific cortical activation patterns, which correlate
with performance benefits. Increased expression of two mRNAs
encoding gamma-aminobutyric acid (GABA-A) receptors (GA-
BRA1 and GABRA2) and one GABA-B receptor (GABBR2) in IAD
patients, may indicate GABAergic terminal sprouting and suggests
that inhibitory compensatory mechanisms may also be activated,
perhaps due to aberrant increases in network excitability as in the
hAPP transgenic mouse [65].
dAb accumulate as MMSE declines
The dimeric form of Ab1-42 becomes detectable on Western
blots of the prefrontal cortices of our IAD patients, and further
increases with advancing dementia. Our data (Figure S3) suggests
that oligomers, other than the dimer, do not show accumulation
concurrent with dementia. In experimental mouse models, Ab
dimers or trimers are implicated and produce transient brain
dysfunction in the absence of plaques detected neuropathologically
[14]. Accumulation of dAb in Tg mice also occurs concurrently
with memory impairment [12]. In experiments using extracts from
AD brains, dAb is shown to have a primary role in impairment of
plasticity in rodent slice cultures and to disrupt memory function
in rats trained on a step-through passive avoidance task [66].
We found that dAb is more abundant in whole homogenates
than in synaptoneurosome fractions suggesting only a small
portion of total dAb is associated with synaptic membrane or
present in the postsynaptic compartment [3,12]. The prefrontal
cortices of two control and three IAD patients have some amyloid
plaque accumulation (Table S1), but Ab1-42 is reported in
susceptible neurons of IAD patients even before plaque pathology
is apparent. dAb is not detected in control patients except for one
individual (Figure 2) with an ApoE3/4 genotype but normal
MMSE and CDR scores. Increased ApoE mRNA expression in
IAD patients (Table 2), may augment the effects of the ApoE4
allele, a major genetic risk factor for AD that leads to excess
amyloid buildup in the brain before AD symptoms arise.
Synaptic mRNA and local translation
The de novo synthesis of proteins in response to receptor
activation is an essential component of plasticity effecting
immediate changes in the balance of local constituent proteins at
the synapse [33,67–69]. Many of the mRNAs with the greatest
fold change in our study encode putative mRNA binding sites in
the 39UTR which regulate local protein synthesis through
interacting binding proteins (Table S5). In fact, our results may
underestimate the percentage of mRNAs encoding regulatory site
as not all potential regulatory sites were examined. For instance,
mRNA for the atypical brain specific isoform of protein kinase C
zeta (PKMf) is transported to dendrites and co-localizes with BC1
mRNA, a translational repressor [70]. Nevertheless, these results
support the strategy of isolating synaptoneurosomes for boosting
synaptic terminal mRNAs revealing expression changes previously
undetectable in whole homogenates.
GluR2 mRNA is present in a high proportion of dendrites in the
frontal cortex, as it is in hippocampal neurons, [71] and is targeted
for activity-dependant protein synthesis, [69,72] Three putative
consensus sequences encoded in GluR2 mRNA, specifically, a
CPE-like binding sequence [73], a G-quartet and a putative
pumilio binding domain (Table S3) provide potential diverse and
versatile mechanisms for regulation of GluR2 translation. CPE-like
consensus sequence sites are crucial for dendritic plasticity and
thus for learning and memory [33]. As yet, only one mechanism
has been determined for regulation of GluR2 translation, mediated
via Type 1 metabotropic glutamate receptors (mGluRs) [72]. In
accord with this, we found that GluR2 encodes a G-quartet
sequences in the 39UTR (Table S5) and a preceding G-rich
sequence consistent with this mechanism [47,74], suggesting that
GluR2 is a potential target of FMRP. Putative G-quartet structures
were encoded by several other mRNAs, although regulation by
FMRP has not been demonstrated for these genes.
Two mRNAs encoding RNA-binding proteins, HuD and the
pumilio homolog 1, showed increased expression in IAD. Our
study did not reveal a change in expression of CPEB1 and FMR1,
the most studied regulators of protein synthesis at the synapse.
Ab and GluR2 mRNA regulation in IAD
Our results indicate increased mRNA expression of several
neurotransmitter receptors in IAD with the GluR2 subunit of the
AMPA receptor and the muscarinic cholinergic receptor 3
(CHRM3) showing the greatest change. Feedback on transcription
may contribute to an increase in postsynaptic receptor mRNA. In
primary rat hippocampal cultures, NMDAR signaling inhibits
transcription and decreases GluR1 and GluR2 mRNA in dendrites
[71]. Speculatively, as Ab binding to the a-7-nicotinic acetylcho-
line (ACH) receptor induces NMDAR endocytosis [9] thereby
reducing NMDA receptor activation and signaling, disinhibition of
GluR2 gene transcription may follow. Consequently, a larger pool
of somal GluR2 mRNA may be available for subsequent targeting
and transport to dendrites in response to signaling via Group 1
Genes Overexpressed in IAD
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dent increase in dendritic GluR s through transport from the soma
[71]. Although the mechanism is currently uncertain our data
suggests that in IAD there is an increase in transport of some
mRNAs to the synapse.
Muscarinic acetylcholine receptor M3
Several studies have suggested that targeting muscarinic
receptors in AD patients may have therapeutic benefit. For
instance, agonist stimulation of the M1 and M3 receptors in
human cell cultures increases APP release but downregulates the
amyloidogenic pathway leading to Ab production [75,76]. In
accord, rats treated with a muscarinic agonist show decreased
levels of APP in neocortex, hippocampus and striatum along with
a decrease in Ab suggesting an enhancement of the non-
amyloidogenic pathway [77]. The neuroprotective effect of
muscarinic transmission is also seen in studies with the 36Tg-
AD mouse model of AD in which, after treatment with an M1
muscarinic agonist, mice showed a decrease in cognitive decline
and an accompanying reduction in Ab and tau pathology [78].
Since activation of the M3 receptor has similar effects on APP
processing, increase in M3 mRNA may be a compensatory
mechanism in IAD patients responding to Ab overproduction.
GluR2-interacting molecules: inhibitory and
compensatory mechanisms?
Previous studies on GluR2-interacting proteins which, in our
study, are overexpresssed in IAD, lend credence to the notion that
both inhibitory and compensatory mechanism are driven by these
genes. For instance, adenatomous polyposis coli (APC) which is
highly expressed in developing brain is required for AMPAR
activity, facilitating clustering of both AMPARs and PSD-95 at the
synapse and inducing AMPAR activity [79,80] . Also PKMf,a n
atypical protein kinase C isoform, regulates movement of
AMPARs to the synapse and maintains them in late LTP
[81,82]. Notably though, PKMf does not play a role in the
establishment of short-term memory [82] which is most at risk in
incipient and early AD.
Overexpression of other genes, may have a negative effect on
AMPAR mediated excitatory currents. The short splice variant of
Homer, 1a, which is expressed in response to synaptic activity,
reduces surface AMPARs and depresses AMPAR postsynaptic
currents [83]. Thus an increase in Homer mRNA, might result in
higher levels of Homer 1a, perhaps in response to the excitotoxic
effects of oAb in IAD patients, intensifying the negative feedback,
activity dependant loop regulating the structure and function of
synapses. However, to our knowledge, the effect of oAb on Homer
expression has not been investigated. Dynamin also regulates
removal of AMPARs from the membrane and GluR2 undergoes
constitutive and ligand-induced internalization that requires the
clathrin adaptor complex AP-2 in addition to dynamin [84,85].
GluR2 subunit regulation, oAb and neuroplasticity
The accumulation of toxic Ab oligomers in IAD is particularly
relevant to GluR- mediated plasticity as Ab perturbs basal
glutamatergic synaptic transmission in rat cortical slices by a
selective reduction in postsynaptic, AMPAR-mediated currents
[86]. Our data suggests that the increase in synaptic GluR2 results
in a corresponding increase in protein expression at the synapse in
IAD patients. The GluR2 subunit defines the properties of
AMPARs which are heteromers, consisting mainly of GluR1 and
GluR2 subunits in the mature brain [87]. GluR2 insertion
maintains the receptors in a low conductance state and NMDAR
activation is required to induce a rapid incorporation of GluR1,
forming Ca
++ permeable AMPAR homomers which are required
for LTP [88]. Although we show an increase in relative amounts of
synaptoneurosome-bound GluR2 subunits in IAD compared to
control, we do not yet know if they are synaptic, extrasynaptic or
internal. However it is reported that, in primary cultures of rat
hippocampal neurons, chronic treatment with Ab diffusible
ligands induces an aggregation of GluR2 on the surface of
dendrites [89] as well as driving the loss of surface GluR1 subunits
by endocytosis leading to LTD [90], and ultimately, loss of
dendritic spines and synapses. Impeding the influx of Ca
++ into
neurons through insertion of GluR2 into AMPARs may be a
response to dAb that is initially neuroprotective but which
eventually leads to synaptic depression, and in AD patients,
cognitive impairment.
These findings may provide targets for pharmaceutical
intervention, either to moderate negative impact of Ab on
cognition via GluR2 or to stimulate compensatory activity. Also
our approach using synaptoneurosomes from human brain may be
useful for elucidating molecular abnormalities at the synapse in
other diseases of the brain such as Parkinson’s disease and
schizophrenia.
Materials and Methods
Disclosure statement
Approval for patient neuropsychological testing (IRB approval
# 002003) and for harvesting of the brain at autopsy (IRB
approval # 042071) was obtained from the USC Health Sciences
Institutional Review Board. Written informed consent was
obtained from all participants during an interview conducted by
the Clinical Core of the ADRC in which patients were invited to
enroll in the study.
Neuropsychological and Neuropathological Assessment
Neuropsychological and Neuropathological Assessment of the
control and IAD patients are explained in Supplemental Methods
S1.
Preparation of Synaptoneurosomes
Blocks (1 cm
3) were obtained from prefrontal cortices (Brod-
mann’s areas 9, 10) at autopsy from a total of 14 patients; 8
controls, and 6 IAD, immediately snap-frozen and stored at
290uC. Four samples, 2 controls and 2 IADs, with additional
available tissues were re-analyzed as duplicates for microarrays.
Synaptoneurosomes were prepared by a standard method with
slight modifications [35,37,74,91]. Frontal cortex (0.5 gm–2.5 gm)
was thawed and homogenized with a Teflon-homogenizer (4
strokes at 1000 rpm) in buffer (1/10wt/vol), containing 0.35 M
sucrose pH 7.4, 10 mM 4-(2-hydroxyethyl)-1-piperazineethane-
sulfonic acid (HEPES), 1 mM ethylenediaminetetraacetic acid
(EDTA), 0.25 mM dithiothreitol, 30 U/ml RNAse inhibitor and a
protease inhibitor cocktail (Pierce, Rockford, Il). Cell debris and
nuclei were removed by centrifugation at 1000 g for 10 min at
4uC yielding pellet P1 and supernatant S1. The S1 fraction was
passed sequentially through a series of screens with decreasing
pore sizes of 100, 80, 30 and 10 mm. The final filtrate was
resuspended in 3 volumes of buffer without sucrose and
centrifuged at 20006g, for 15 minutes at 4uC to yield a pellet
containing synaptoneurosomes. Total preparation time did not
exceed 1 hour. For detection of nuclear contamination, 5 mlo f
homogenate (2 ml total volume), P1 (0.5 ml) or synaptoneurosome
pellets (0.1 ml total volume) were smeared and air-dried onto
microscope slides then fixed in ice-cold acetone for 5 minutes.
Genes Overexpressed in IAD
PLoS ONE | www.plosone.org 9 March 2009 | Volume 4 | Issue 3 | e4936Nuclei were labeled by addition of mounting media containing
DAPI. Representative fields at 206 magnification from homog-
enate, P1 and synaptoneurosome fractions were counted to assess
nuclear content. Synaptoneurosome pellets were snap-frozen for
mRNA preparation or suspended in incubation buffer. Some
samples were prepared for electron microscopy by fixation in 1%
paraformaldehyde/0.1% glutaraldehyde, postfixed in 1% osmium
tetroxide, washed in phosphate buffer then further processed as
detailed by Johnson et al (1997).
Total RNA isolation and microarray preparation
Total RNA from synaptoneurosome preparations was extracted
with Trizol LS (Invitrogen Carlsbad, California 92008) and
purified with RNeasy columns (Qiagen, Valencia CA 91355). The
RNA was quantified and checked for purity by comparison of
absorbance at 260 and 280 nm in the Nanodrop Spectrophotom-
eter (Nanodrop, Wilmington, DE 19810). Total RNA and mRNA
were analyzed for integrity and concentration by microanalysis in
an Agilent bioanalyzer (Agilent Santa Clara, CA 95051). Probes
for array analysis were prepared according to the Affymetrix
protocol using 10 mg total RNA as a template to generate cDNA
probes for hybridization. Biotinylation and amplification of cDNA
was accomplished by the use of an Enzo BioArray High Yield
RNA Transcript Labeling Kit (Enzo Life Sciences, New York,NY)
followed by purification by absorption over an RNeasy column
(Qiagen). Hybridization to the HG-U133A (Affymetrix) was
performed according to standard Affymetrix protocols. The
hybridized array was washed, labeled with phycoerythrin-
conjugated streptavidin (Molecular Probes, Eugene, OR) and
scanned in an Affymetrix scanner.
Data analysis
Microarray Analysis Suite 5.0 (MAS 5.0) was used for the initial
signal analysis which generates a signal detection value based on
the difference between the perfect match (PM) and mismatch
(MM) probes in a probe set. A ‘present’ or ‘absent’ call was
assigned to each gene by MAS 5.0 according to certain threshold
and the detection p-values. The microarray data was checked for
RNA degradation, visible defects in images, and Affymetrix
hybridization control by Bioconductor Affymetrix package
(http://www.bioconductor.org/) [92,93]. Model-Based Expres-
sion Index (dChip) [94] implemented in Bioconductor, was used
for signal normalization within an individual chip and across all
samples. For high-level analysis, statistics tests were conducted to
find significantly expressed genes, and this small set of genes was
applied for clustering and pathway analysis. Probe sets that were
differentially expressed among control and IAD were identified
using ANOVA. Benjamini and Hochberg’s False Discovery Rate
(FDR) was used for adjusting for multiple testing. The genes with
significant change in expression were subject to hierarchical
clustering using dChip. Gene annotation and gene ontology
grouping was identified with the Expression Analysis Systematic
Explorer or EASE (http://david.abcc.ncifcrf.gov/ ) for assignment
of significantly expressed genes to Gene Ontology Consortium
categories (http://www.geneontology.org). Functional grouping of
genes and pathways were further explored with Ingenuity Pathway
Analysis, (IngenuityH Systems http://www.ingenuity.com). The
p,0.01 dataset containing gene identifiers and corresponding
expression values was uploaded into the application. Each
identifier was mapped to its corresponding gene object in the
Ingenuity knowledge base. For this analysis a fold change of $1.2
was set to identify genes whose expression was significantly
differentially regulated. These genes, called focus genes, were
overlaid onto a global molecular network developed from
information contained in the Ingenuity knowledge base. Networks
of these focus genes were then algorithmically generated based on
their connectivity.
The 39UTR CPE-element important in mRNA processing at
the synapse was identified using UTRScan at http://bighost.ba.
itb.cnr.it/BIG/UTRScan/ [46] and AU-rich sequences were
identified using the search tool at http://brp.kfshrc.edu.sa/
ARED/ A further analysis, using ESPSearch [95] was carried
out for mRNAs bearing CPE-like sequences using broadened
criteria. [45]. A detailed explanation of 39UTR analysis is
explained in Supplemental Methods S1.
Independent validation of the microarray data by real
time quantitative PCR
Genes of interest and showing significant alterations in
expression were used for RT-PCR analysis with gene-specific
amplification primers to confirm the array results. b-2-micro-
globulin (b-2M) probe was used as a normalization control.
Briefly, 2 mg total RNA was used to generate cDNA by reverse
transcription using oligo dT primers. Subsequently, the cDNA
product was used for the quantitative PCR reaction in the DNA
Engine Opticon 2 Continuous Fluorescence Detection System
(BioRad) using SYBR Green chemistry with the DyNamo HS
kit (New England Biolabs, Ipswitch, MA). Evaluation samples
were run in triplicate with 10-fold serial dilution. Signal
intensity to cycle number was monitored during the run. The
differential mRNA expression of each studied gene was
calculated with the comparative Ct method using the formula
2
DDCt where DCt stands for the difference between the target
gene and the endogenous control b-2M, adjusted by the Ct
d i f f e r e n c eb e t w e e nt h e s e2g e n e si nn e g a t i v ec o n t r o l s ,a n dDDCt
equals to the difference between the DCt value of the target
gene in samples.
In vitro translation
Two reactions were set up using mRNAs isolated from
synaptoneurosomal preparations of pooled human normal con-
trols or pooled AD-affected frontal cortex, and containing
exogenous cellular components, the rabbit reticulocyte lysate
(RRL) necessary for protein synthesis. Each reaction contained
RRL (37 ml); (Promega; Madison,WI), nuclease free water (10 ml),
1 mM amino acid mix (1 ml), RNAsin (1 ml), RNA template (2 ml);
The components were thoroughly mixed before addition of
Transcend tRNA (2 ml); (Promega; Madison,WI). A no-template
control was also included to distinguish endogenous biotinylated
proteins from newly synthesized translation product. To establish
that preparations retained independent basal translation capabil-
ity, reactions containing synaptoneurosomes but not RRLs were
tested. Each reaction contained synaptoneurosomes (10 mg protein
in 37 ml translation buffer) from a control patients brain, nuclease
free water (10 ml),1 mM amino acid mix (1 ml), RNASin (1 ml) and
Transcend t-RNA(2 ml). Control reactions contained either the
translation inhibitor anisomycin (40 mM) or the transcription
inhibitor actinomycin D (5 mgi n5 0ml). Five further reactions
were set up as described with synaptoneurosomes from 3 controls
and 2 MCI patients and incubated for 40 minutes at 30uCt o
determine the repeatability of the translation capability in
synaptoneurosomes from human brain autopsy tissue. The
reactions were incubated for 40 minutes at 30uC and 10 ml
applied to gels for detection of biotinylated proteins on Western
blots with streptavidin-horseradish-peroxidase conjugate (GE
Healthcare, Piscataway, NJ) followed by Supersignal West
FEMTO chemiluminescent substrate.
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Enrichment and stability of proteins in homogenates and
synaptoneurosomes were analyzed on Western blots with the
following antibodies: anti PSD95 (MAB1596), NMDAR1
(MAB363)., and GluR2 (AB1768-25UG ), SNAP25, and GAPDH
(MAB374) all from Chemicon; Temecula, CA. bIII Tubulin
(Abcam; Cambridge MA) and PKCa,and GFAP (Santa Cruz
Biotechnology; Santa Cruz, CA) were used to detect cytoplasmic
and glial proteins. MAb 4G8 (Abcam, Cambridge,MA) was used
for Ab peptide detection. Samples were separated on 5–15 or 10–
20% gradient tris-glycine polyacrylamide gels and electrotrans-
ferred to nitrocellulose at 100 V for 2 hours. Membranes were
incubated overnight at 4uC with primary antibodies and then with
horseradish-peroxidase-linked (HRP) secondary antibodies (Pierce;
Rockford, IL) for 1 hour. The signal was detected with ECL
reagent (GE Healthcare; Piscataway, NJ).
Densitometry and Statistical Analysis
Immunoblots were scanned and assessed by densitometry with
AlphaEase
TM v5.5 software. The ratio of GluR2 or dAb to
GAPDH is given in arbitrary units based on the integrated density
value which is the sum of all pixel values after background
correction (IDV). Values are presented as mean6SEM.. Com-
parisons were made between control and IAD using ANOVA. A
p-value of less than 0.05 was considered statistically significant.
Supporting Information
Supplemental Methods S1
Found at: doi:10.1371/journal.pone.0004936.s001 (0.09 MB
PDF)
Table S1 Neuropsychological and Neuropathological Assess-
ment of Patients. The IAD group and the normal control group
were not statistically different with regard to age, years of
education, gender distribution, or interval between testing and
death. As expected, the IAD group obtained lower scores on the
MMSE than normal controls (p,0.01). MMSE scores ranged
from 25 to 29 for normal controls and from 21 to 27 for IAD. No
statistically significant difference was detected between NC and
IAD for performance on either the composite measure or Digit
Span backward. Statistical comparisons on each measure were
made by Mann-Whitney U tests.
Found at: doi:10.1371/journal.pone.0004936.s002 (0.02 MB
PDF)
Table S2 Differentially Expressed Genes in IAD (p,0.01) with
fold change, p-values and RefSeq Summary.
Found at: doi:10.1371/journal.pone.0004936.s003 (0.21 MB
XLS)
Table S3 Ingenuity Functional Analysis. Genes comprising the
two most significant categories, Cell-to-Cell Signaling and
Interactions and Nervous System Function and Development.
Found at: doi:10.1371/journal.pone.0004936.s004 (0.04 MB
XLS)
Table S4 Network representation of the biological processes
generated by genes upregulated in IAD. The data set containing
gene identifiers and corresponding expression values for the
overexpressed C v IAD genes in the p,0.01 group were uploaded
and overlaid onto a global molecular network developed from
information contained in the Ingenuity Pathways Knowledge
Base. Each gene identifier was mapped to its corresponding gene
object in the Ingenuity Pathways Knowledge Base. Networks of
these focus genes were then algorithmically generated based on
their connectivity. Our genes fell into 24 Ingenuity defined
networks.
Found at: doi:10.1371/journal.pone.0004936.s005 (0.02 MB
XLS)
Table S5 Regulatory elements present in the 39UTR of genes
important for nervous system function and development. The
39UTR of each gene with changed expression in IAD was
analyzed for four potential consensus sequence sites regulating
translation; the cytoplasmic polyadenylation element (CPE), the
FMRP binding G-quartet, the AU-rich element which binds to the
mRNA binding protein HuD, and a putative pumilio binding site.
At least one of these putative regulatory sequence(s) is encoded in
the 39UTR of 24 out of 49 total genes and 3 and 10 of these
contain more than one regulatory sequence. Twenty-five mRNAs
do not contain any of the consensus sequences although two of
these genes, GAP-43 and neurogranin, important for neuroplas-
ticity, are known to encode other regulatory elements. Reported
genome content of the regulatory sequences is included at the
bottom of the relevant column.
Found at: doi:10.1371/journal.pone.0004936.s006 (0.31 MB
XLS)
Figure S1 Functional Stability of Synaptoneurosome mRNA.
A)To test stability of mRNA from synaptoneurosomes, pooled
mRNAs from control tissues were combined with rabbit
reticulocyte lysates (RRL) and Transcend
TM tRNA, which is an
e-labeled, biotinylated lysine-tRNA complex with a detection
sensitivity of 0.5–5 ng of protein, and the resulting biotinylated
proteins detected by Western immunoblot. In combination with
rabbit reticulocyte lysate (RRL) and Transcend
TM biotinylated t-
RNA the isolated mRNAs from control (lane 2) and AD tissues
(lane 3) yielded several biotinylated species indicative of newly
synthesized proteins seen between 70–90 kD (two bands), ,60 kD
and ,50 kD, and two bands .30 kD. The identity of these
proteins is undetermined. A no-template control, with RRLs only,
shows that bands at ,70D (also in Control and AD lanes) and
30 kD are endogenously biotinylated proteins (asterisks). B) In
vitro translation function of synaptoneurosomes is maintained in
the 5 patients tested, regardless of clinical stage of disease. Asterisks
denote endogenously biotinylated species.
Found at: doi:10.1371/journal.pone.0004936.s007 (0.20 MB
PDF)
Figure S2 Immunoblots of Homogenates and Synaptoneuro-
somes Probed with MAbs 4G8 and 6E10. A) Only the band
coinciding with dimeric Ab (,9 KD, arrowhead)is correlated
with declining MMSEs or ApoE genotype in homogenates or
synaptoneurosomes. B) Densitometry reveals that, when nor-
malized to GAPDH, dimeric Ab but not tetrameric Ab levels
are inversely related to MMSE. Because of small n and
variability within groups, differences between groups is not
significant . dAb C v IAD p=0.35, C v AD p=0.12. tAb Cv
IAD p=0.99, C v AD p=0.44 C) Immunoblots of control
(lane1), IAD (lane2) and AD patients (lane 3,4) probed with
antibodies 6E10 and 4G8 revealed labeling of dAb only in
patients with cognitive decline.
Found at: doi:10.1371/journal.pone.0004936.s008 (0.10 MB
PDF)
Figure S3 Ingenuity Functional Analysis. The Functional
Analysis identifies the biological functions and/or diseases that
were most significant to the data set. Genes from the p,0.01
dataset with fold change $1.2 in IAD patients were used for the
analysis. Fischer’s exact test was used to calculate a p-value
determining the probability that each biological function assigned
Genes Overexpressed in IAD
PLoS ONE | www.plosone.org 11 March 2009 | Volume 4 | Issue 3 | e4936to that data set is due to chance alone. Threshold is at 1.3=2log
(p,0.05).
Found at: doi:10.1371/journal.pone.0004936.s009 (0.03 MB
PDF)
Figure S4 Network representation of the biological processes
generated by genes upregulated in IAD. The Neurological Disease
Network contains 37genes, 22 of which are focus genes
upregulated in IAD (Figure S4A). Increased expression of two
mRNAs encoding gamma-aminobutyric acid (GABA-A) receptors
(GABRA1 and GABRA2) and one GABA-B receptor (GABBR2)
in IAD patients, may indicate GABAergic terminal sprouting and
suggests that inhibitory compensatory mechanisms may also be
activated The Nervous System Development and Function
Network (Figure S4B) contains 26 genes 17 of which are
upregulated in IAD. In Figure S4C, Network 4 in subcellular
layout, the functional significance of GluR2 (GRIA2) is seen by the
addition of up- and downstream interacting molecules to the
network. Notably, GluR2 is a potential target of FMRP. Other
significant GluR2-interacting molecules, dynamin, AP-2 and
Homer, are not represented in this chart. Genes overexpressed
in IAD are seen in pink with fold change. All networks are listed in
Table S4.
Found at: doi:10.1371/journal.pone.0004936.s010 (0.71 MB
PDF)
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